Cell Signaling Technology

Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.

sample review
  • Anti-LC3 antibody was used for immunoassay, in order to demonstrate engineering of electrically and chemically responsive, contractile human muscle tissues using primary myogenic cells
  • Anti-phospho-PKA substrate antibody was used for Western blotting, in order to demonstrate optogenetics as a useful tool for controlling fertilization and cAMP signaling in sperm.
  • Anti-S6 ribosomal protein antibody was used in this study to perform ribosome profiling on cultured human cells under conditions of severe stress induced with sodium arsenite.
  • Anti-phospho-S6 ribosomal protein antibody was used in this study to perform ribosome profiling on cultured human cells under conditions of severe stress induced with sodium arsenite.
  • Anti-phospho-p70 S6 kinase antibody was used in this study to perform ribosome profiling on cultured human cells under conditions of severe stress induced with sodium arsenite.
  • Anti-phospho FAK antibody was used for cell culture, in order to study the effect of extrusion defect on carcinogenesis and tumor progression
  • SignalStain Boost IHC detection reagent was used for immunofluorescence analysis, in order to investigate the effect of inhibition of mutant EGFR in lung cancer cell on SOX2-FOXO6-dependent survival pathways.
  • Anti-FOXO3 antibody was used for immunoblot analysis, in order to investigate the effect of inhibition of mutant EGFR in lung cancer cell on SOX2-FOXO6-dependent survival pathways.
  • Anti-FOXO1 antibody was used for immunoblot analysis, in order to investigate the effect of inhibition of mutant EGFR in lung cancer cell on SOX2-FOXO6-dependent survival pathways.
  • Anti-phospho-FOXO1 antibody was used for immunoblot analysis, in order to investigate the effect of inhibition of mutant EGFR in lung cancer cell on SOX2-FOXO6-dependent survival pathways.
  • Anti-BIM antibody was used for immunoblot analysis, in order to investigate the effect of inhibition of mutant EGFR in lung cancer cell on SOX2-FOXO6-dependent survival pathways.
sample product